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Abstract
Depression is a disease that effects millions of patients and has a 
variety of symptoms. It is primarily defined by depressed mood 
and anhedonia. The first line treatment for depression is SSRI 
medications. These medications have several side effects and are 
not effective for a large number of patients. Therefore, this study 
was done to review ketamine as a new treatment option for 
depression and see how it compares to a placebo.
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Introduction
Methods
Literature Search
• Performed in November 2018 
• Performed on PubMed and Ebscohost
• Keywords were Ketamine and Depression
• Only included randomized control studies
• Papers had to be published within the past 5 years
All of the studies that compared ketamine specifically to a 
placebo showed a statistically significant improvement in 
the MADRS score
Important take a ways:
• Of the 5 studies that compared ketamine to placebo, 3 
used the QIDS-SR score in addition to the MADRS score, 
all of which showed a significant reduction with ketamine
• The two studies that did not show statistical significance 
still showed an improvement on depressive symptoms, 
they did not however compare to placebo
Limitations:
• The largest sample size was only 72 patients
• Most studies focus on severe treatment resistant 
depression
Discussion Results 
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In individuals diagnosed with moderate to severe depression, does the use of 
ketamine provide equal or greater relief from symptoms when compared to the use 
of a placebo treatment?
Over all the research performed for this study showed 
extremely promising results. All of the studies that 
compared placebo and ketamine showed statistically 
significant decrease in depressive symptoms based on 
MADRS and QIDS-RS scores. Larger studies with more 
participants are needed to fully understand the effect that 
ketamine has on patients, but for now it looks promising as 
a new treatment for depression 
Conclusion
• Lally N, Nugent, Luckenbaugh Et al.
❖RCT of 36 patients comparing Ketamine to placebo (NSS)
• Price RB, Iosifescu DV, Murrough JW, et al.
❖RCT of 57 patients comparing Ketamine to Placebo
(Midazolam)
• Murrough JW, Iosifescu DV, Chang LC, et al
❖RCT of 72 patients comparing Ketamine to Placebo
(Midazolam)
• Lapidus KA, Levitch CF, Perez AM, et al
❖RCT of 20 patients comparing Ketamine to Placebo (NSS)
• Fan W, Yang H, Sun Y, et al
❖RCT of 37 patients comparing Ketamine to Placebo
(Midazolam)
• Lenze EJ, Farber NB, Kharasch E, et al
❖RCT of 20 patients comparing Ketamine treatment
duration
Major Depressive Disorder(MDD)
Overview:
• Affects 16 million people annually
• Over 30,000 suicide deaths annually in the US alone
Symptoms:
• Requires a 2 week period of either anhedonia or depressive mood
• Can also present with: fatigue, insomnia, hypersomnia, feelings of 
worthlessness, suicidal thoughts
Treatment:
• Firstline treatment is with SSRI
• Other treatments include SNRI, TCA, and MAO inhibitors
Study Reduction in 
MADRS Score
Reduction in 
QIDS-SR
Duration of 
treatment 
effect
Reduction of 
additional 
symptoms
Lally N, Nugent, 
Luckenbaugh Et 
al.
S NA S S
Price RB, 
Iosifescu DV, 
Murrough JW, 
et al.
S S NA S
Murrough JW, 
Iosifescu DV, 
Chang LC, et al
S S S S
Lapidus KA, 
Levitch CF, 
Perez AM, et al
S S NS NA
Fan W, Yang H, 
Sun Y, et al
S NA S at day 3
NS at day 7
NA
Lenze EJ, Farber 
NB, Kharasch E, 
et al
NS NA NS NS
Vande Voort JL, 
Ballard ED, 
Luckenbaugh 
DA, et al
NS NA NA S
S = Statistically Significant, NS = Not Significant, NA = Results Not Available
